secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2026-07-15T13:03:18+00:00
Accession:  0001193125-26-304126
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GSK completes $10.6B acquisition of Nuvalent; tender offer accepted, merger effective July 15, 2026
--------------------------------------------------------------------------------

- Tender offer closed with 91.3% of shares tendered; all validly tendered shares accepted at $124.00 per share.
- Merger completed under DGCL Section 251(h); Nuvalent becomes wholly owned subsidiary of GSK.
- Total equity value approximately $10.6 billion; funded from GSK credit facilities.
- All prior directors and officers resigned; replaced by GSK appointees (Justin Huang, Kevin Ryan, Hatixhe Hoxha).
- Shares to be delisted from Nasdaq; company intends to file Form 15 to suspend SEC reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526304126/0001193125-26-304126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526304126/d52896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-304126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer